EKF Diagnostics Investor Announcements


EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Further announcement regarding the exclusive license and collaboration agreement with Icahn School of Medicine at Mount Sinai in New York, USA.

Renalytix AI plc to develop Artificial Intelligence for early identification and management of kidney disease.

8th May 2018

Annual Report and Accounts for the year ended 31 December 2017 now available.

EKF announces US Food and Drug Administration 510(k) clearance and CLIA waiver for DiaSpect Tm.

Notification of major holdings. 

14th Mar 2018

EKF Diagnostics announces its final results for the year ended 31 December 2017.

EKF Diagnostics announces that it will release its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.

11th Jan 2018

EKF Diagnostics provides shareholders with the following update on current trading. 

29th Dec 2017

As at 29 December 2017, the Company's total issued share capital consists of 457,554,636 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds no Ordinary Shares in treasury.